Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pharm Pharmacol ; 62(8): 985-94, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20663032

RESUMO

OBJECTIVES: Our aim was to investigate the effect of PEGylation on the uptake of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) into rat liver, kidney and spleen, and human liver. METHODS: Copolymer of polyethyleneglycol allylmethylether and maleamic acid sodium salt with OCIF (poly(PEG)-OCIF) (0.5 mg/kg) was administered to rats and the concentrations of poly(PEG)-OCIF in the liver, kidney and spleen at 15 min after administration were measured by ELISA. For human liver uptake, the liver perfusion of OCIF and (3)H-labelled poly(PEG)-OCIF was conducted using fresh human liver block. KEY FINDINGS: The tissue uptake of poly(PEG)-OCIF in rats was significantly lower compared with that of OCIF. In fresh human liver perfusion, (3)H-poly(PEG)-OCIF was rarely taken up into the liver. On the other hand, more than 50% of the perfused OCIF was taken up. CONCLUSIONS: PEGylation of OCIF using poly(PEG) dramatically suppressed the uptake of OCIF into human liver as well as into rat liver and could be a promising approach for improving the pharmacokinetic and pharmacological effects of OCIF in the clinical setting.


Assuntos
Conservadores da Densidade Óssea/farmacocinética , Fígado/metabolismo , Osteoprotegerina/farmacocinética , Polietilenoglicóis/química , Animais , Transporte Biológico , Conservadores da Densidade Óssea/administração & dosagem , Conservadores da Densidade Óssea/sangue , Conservadores da Densidade Óssea/química , Células Cultivadas , Química Farmacêutica , Regulação para Baixo , Ensaio de Imunoadsorção Enzimática , Feminino , Heparina/metabolismo , Humanos , Injeções Intravenosas , Rim/metabolismo , Maleatos/química , Camundongos , Osteoclastos/efeitos dos fármacos , Osteoprotegerina/administração & dosagem , Osteoprotegerina/sangue , Osteoprotegerina/química , Ovariectomia , Perfusão , Ratos , Ratos Sprague-Dawley , Baço/metabolismo , Distribuição Tecidual
2.
Clin Calcium ; 15(1): 35-42, 2005 Jan.
Artigo em Japonês | MEDLINE | ID: mdl-15632471

RESUMO

Osteoclastogenesis inhibitory factor (OCIF) is a novel member of the Tumor Necrosis Factor Receptor superfamily and identical with Osteoprotegerin (OPG) discovered by Amgen researchers. OCIF/OPG is a decoy receptor (a soluble receptor that acts as an antagonist) that binds to osteoblast cells via Receptor Activator of NF-kappa B Ligand (RANKL) involved in the signal transduction between osteoblast cells and osteoclastic progenitor cells, eventually suppressing differentiation of the progenitor cells into osteoclasts. The balance between the OCIF/OPG and RANKL is regulated by cytokines and hormones. Studies on OCIF/OPG-RANKL system have provided important insights into the pathogenesis of human metabolic bone diseases, leading to the expectation of OCIF/OPG as a novel candidate for a therapeutic agent for metabolic bone diseases.


Assuntos
Glicoproteínas , Osteoporose/tratamento farmacológico , Receptores Citoplasmáticos e Nucleares , Animais , Osso e Ossos/metabolismo , Proteínas de Transporte/fisiologia , Diferenciação Celular/genética , Ensaios Clínicos como Assunto , Desenho de Fármacos , Glicoproteínas/química , Glicoproteínas/fisiologia , Glicoproteínas/uso terapêutico , Humanos , Glicoproteínas de Membrana/fisiologia , Osteoblastos , Osteoclastos/citologia , Osteoporose/etiologia , Osteoprotegerina , Ligante RANK , Receptor Ativador de Fator Nuclear kappa-B , Receptores Citoplasmáticos e Nucleares/química , Receptores Citoplasmáticos e Nucleares/fisiologia , Receptores Citoplasmáticos e Nucleares/uso terapêutico , Receptores do Fator de Necrose Tumoral , Transdução de Sinais/genética
3.
Phys Med Biol ; 49(14): 3267-77, 2004 Jul 21.
Artigo em Inglês | MEDLINE | ID: mdl-15357196

RESUMO

As the magnetic field of widely used MR scanners is one of the strongest magnetic fields to which people are exposed, the biological influence of the static magnetic field of MR scanners is of great concern. One magnetic interaction in biological subjects is the magnetic torque on the magnetic moment induced by biomagnetic substances. The red blood cell is a major biomagnetic substance, and the blood flow may be influenced by the magnetic field. However, the underlying mechanisms have been poorly understood. To examine the mechanisms of the magnetic influence on blood viscosity, we measured the time for blood to fall through a glass capillary inside and outside a 1.5 T MR scanner. Our in vitro results showed that the blood viscosity significantly increased in a 1.5 T MR scanner, and also clarified the mechanism of the interaction between red blood cells and the external magnetic field. Notably, the blood viscosity increased depending on blood oxygenation and the shear rate of the blood flow. Thus, our findings suggest that even a 1.5 T magnetic field may modulate blood flow.


Assuntos
Viscosidade Sanguínea , Campos Eletromagnéticos , Imageamento por Ressonância Magnética/instrumentação , Magnetismo , Oxigênio/sangue , Oxigênio/metabolismo , Adulto , Sangue/metabolismo , Respiração Celular , Testes Hematológicos , Humanos , Imageamento por Ressonância Magnética/métodos , Masculino , Reologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...